SCHEMBL20260903

SCHEMBL20260903

COc1ncccc1C(N)Nc1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALK Q9UM73 3/20 0.38
SLC6A2 P23975 3/20 0.38
SLC6A4 P31645 3/20 0.38
KMT2A Q03164 2/20 0.36
KCNH3 Q9ULD8 1/20 0.36
CYP3A4 P08684 3/20 0.35
CYP2D6 P10635 3/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
SLC6A3 Q01959 2/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20261105 0.86 VDR (0.55) VDRNPC1RAB9ASLC6A2SLC6A4
SCHEMBL20261096 0.82 P2RY1 (0.47) NPC1RAB9AALKKMT2ACYP1A2
SCHEMBL20261088 0.81 PIK3CA (0.42) VDRNPC1SLC6A2SLC6A4KMT2A
SCHEMBL20261118 0.79 CA1 (0.41) RAB9AKMT2ACYP3A4CYP2D6USP2
SCHEMBL25482252 0.74 NPC1 (0.42) NPC1RAB9AALKSLC6A2SLC6A4
SCHEMBL3055286 0.73 CD274 (0.46) VDRNPC1RAB9ASLC6A2SLC6A4
SCHEMBL30320151 0.73 CD274 (0.46) VDRNPC1RAB9ASLC6A2SLC6A4
SCHEMBL24992088 0.73 CD274 (0.46) VDRNPC1RAB9ASLC6A2SLC6A4
SCHEMBL21831822 0.72 SLC6A2 (0.44) NPC1RAB9ASLC6A2SLC6A4KMT2A
SCHEMBL20261086 0.72 L3MBTL1 (0.39) SLC6A2KMT2AKCNH3CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10653673-B2 Substituted imidazoles as N-type calcium channel blockers JANSSEN PHARMACEUTICA NV (BE) 2020-05-19 US disclosed
US-20180161312-A1 SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS JANSSEN PHARMACEUTICA NV (BE) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10653673-B2 Substituted imidazoles as N-type calcium channel blockers CACNA1B, CACNA1E, CACNA1S VDR 556/4885NPC1 643/4885RAB9A 769/4885
US-20180161312-A1 SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS CACNA1B, CACNA1E, CACNA1S VDR 556/4885NPC1 643/4885RAB9A 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.